The majority of the data supporting TSPO as a potential target for anti-inflammatory treatment in epilepsy are either preclinical or from limited clinical studies, and it is still not clear if TSPO is a more composite measurement of neuroinflammation or if it is specific enough to warrant targeted therapy.17 The gene discussed is TSPO; the disease is epilepsy.